SP-1-303 / Shuttle Pharma - LARVOL DELTA

Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE (GlobeNewswire) - "Shuttle Pharmaceuticals Holdings...announced the publication of a manuscript reporting on the ability of one of the Company’s HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC). The published manuscript, titled 'Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth,' reports the work of Dr. Mira Jung, Professor of Radiation Medicine at Georgetown University Medical Center, and Dr. Scott Grindrod, Shuttle Pharma’s Principal Scientist, and was published in PLOS ONE..."

Preclinical • Estrogen Receptor Positive Breast Cancer

Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth. (PubMed, PLoS One) - "Collectively, SP-1-303 emerges as a novel second generation class I (HDAC1 and HDAC3) selective HDAC inhibitor, and ATM activator, capable of modulating ER expression, and inhibiting growth of ER+ BC cells. Combined targeting of class I HDACs and ATM by SP-1-303 offers a promising therapeutic approach for treating ER+ breast cancers and supports further preclinical evaluation."

Journal • Ataxia • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Movement Disorders • Oncology • Primary Immunodeficiency • Solid Tumor • Triple Negative Breast Cancer • BRCA1 • ER • HDAC1 • HDAC3 • TP53

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform (PRNewswire) - "Shuttle Pharmaceuticals Holdings, Inc...announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled 'Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof.'...The Company's HDAC pre-clinical inhibitor platform includes: SP-2-225 is Shuttle Pharma's pre-clinical Class IIb selective HDAC inhibitor that affects histone deacetylase HDAC6; SP-1-161 is Shuttle Pharma's pre-clinical candidate lead HDAC inhibitor, radiation sensitizing candidate product; SP-1-303 is Shuttle Pharma's pre-clinical selective Class I HDAC inhibitor..."

Patent • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor